Shiv Vardan Singh, Risha Ganguly, Kritika Jaiswal, Aditya Kumar Yadav, Ramesh Kumar, Abhay K Pandey, Department of Biochemistry, University of Allahabad, Allahabad (Prayagraj) 211002, Uttar Pradesh, India
Author contributions: Pandey AK and Singh SV conceptualized the idea; Singh SV, Ganguly R, Jaiswal K, Yadav AK, and Kumar R performed the literature search; Singh SV and Ganguly R wrote the first draft of the manuscript and validated the references; Pandey AK critically reviewed and revised the manuscript; and all authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Abhay K Pandey, PhD, Professor, Department of Biochemistry, University of Allahabad, University Road, Allahabad (Prayagraj) 211002, Uttar Pradesh, India. akpandey23@rediffmail.com
Received: December 24, 2022 Peer-review started: December 24, 2022 First decision: March 23, 2023 Revised: May 9, 2023 Accepted: June 6, 2023 Article in press: June 6, 2023 Published online: July 6, 2023 Processing time: 187 Days and 18.1 Hours
Core Tip
Core Tip: Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder with a dysregulated gut brain communication. Gut microbiota functional characterization is still underappreciated but their roles have been found to be pivotal. Various microbial species and their metabolites with altered composition and diversity have been found to be specific to IBS. Clinical manipulation of these microbial species improved the symptom profile in IBS patients while the associated mechanisms have been identified for a bidirectional communication between gut microbiota and brain. This in turn seems promising for future treatments specific to microbiota manipulation and targeting various cross-talks for the management of IBS and associated symptoms.